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international agencies to mobilize resources to close the gap. The GFATM’s principal 
receptor identified a new international provider of ARVs, accounting for savings of 
USD 910 thousand. Finally, the MoH budgeted, for the first time, USD 1.9 million for 
the procurement of ARVs in 2013; turning the financial gap into a surplus USD 700 
thousand. For 2015 GFATM funding was 0%; however the DR Government covered 
a 100% of ARV needs and they have been executing USD 6.8 millions/per year. The 
decrease of the international financial assistance for ARV, particularly by the GFATM, 
can be covered by the commitment of national resources to bridge the financial gap 
and a more efficient use of the resources already available. The estimation of needs, 
consensus building methodologies, political incidence and advocacy strategies used 
in DR are guarantees of the financial sustainability for the following years.
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The number of newly developed and distributed health apps is legion and they are 
offered by healthcare providers, insurers and private companies alike. Although a 
sound business model is not always perceptible at first hand, it can be observed 
that in many cases payers and providers are either trying to bind patients with lock 
in effects and proprietary protocols or want to gather sensitive personal data for 
further use. New health care programs and solutions are rather made for market-
ing purposes than to serve the individual need of the customer (e.g. patient). Our 
project discusses the urgent need for regulatory rules ensuring that competition 
between providers of these health care apps serves the patients needs and leads 
to an improvement of patient relevant outcomes. In the course of the young lions 
“Health Parliament” the issue at hand was brought up by the authors in the board 
of competition at the example of the chronic disease of diabetes. To highlight the 
importance of continuous support in behavioral change we asked patients about 
their individual incentives and their expectations in a regulatory framework of 
health care competition to satisfy their needs. Following several discussions and a 
delphi-panel like process a regulatory framework was developed which could ensure 
that competitive forces act in a way that the patient’s needs are met for all kind of 
chronic diseases. To align the competitive forces onto patient centered outcomes 
the following aspects need to be addressed: 1) Market access; 2) Quality assurance; 
3) Protection of data privacy; 4) Open standards for interchangeability; 5) Pricing and 
reimbursement mechanisms. With our poster we would like to present our claims 
to an international audience to gain further insights on the topic and to foster the 
discussion into a more patient centered competition.
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BAckground: Maintaining chronic disease patients clinically stable after dis-
charge is an important imperative for avoiding costly hospital readmissions. 
A good understanding of the patient’s clinical risk profile is today considered 
the most important factor predictive of unfavorable patient outcomes. However, 
an often overlooked risk factor is patient behavior and patient decision drivers. 
Insights from the behavioral sciences can shed light on how individuals actu-
ally make decisions. Behavioral sciences have been used in marketing for years 
but are rarely used in the medical field. Recent studies from the UK have shown 
that up to 40% of the costs incurred for readmission/ emergency room visits are 
incurred by patients that should have been taken care of in the ambulatory care 
or at home. The behavioral drivers for these patients vary: not a good image of 
GPs, patients that are overly worried and anxious, an opportunity to get access to 
health care without an appointment. discussion: Not applying insights from the 
behavioral sciences to the medical field carries an important and avoidable cost 
for the health system caring for chronic disease patients. Healthcare should invest 
resources allowing to segment chronic disease patients at discharge, according 
to their behavioral profile, and provide support and education for those patients 
that are likely to burden the emergency rooms and hospitals for non-eligible 
reasons. conclusion: Profiling chronic disease patients at risk of costly hos-
pital readmissions based on insights from the behavioral sciences represents an 
opportunity to address an important cost driver that is currently overlooked in 
relation to the traditional clinical risk assessment.
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BAckground: Sofosbuvir, a breakthrough anti-HCV (hepatitis C virus) polymer-
ase inhibitor, was first approved for early entry in 2012 in France. The product was 
granted a marketing authorisation in the United-States (US) and in the European 
Union (EU), by the end of 2013 and beginning of 2014, respectively. Shortly after 
licensing, most HTA bodies assessed sofosbuvir; they acknowledged a major addi-
tional benefit and find it cost-effective for a price around USD 80,000 in US and 
USD 55,000 in EU for a 12-week course treatment. discussion: Sofosbuvir price 
may have led to health insurances (HI) bankruptcy in EU and to substantially 
increase HI premium in US. In EU, politicians reacted through an orchestrated 
media campaign; manufacturer was called to clarify the gap between production 
cost and price, as if price cost was the drug industry model, while value-based 
pricing was in force. The most active campaign happened in France where mem-
bers of parliament and Health Minister multiplied press releases and presence 
through legislative changes. Formal RSA should be mainly a non-outcome based as 
from health outcome based pay for performance looks the most feasible, consider-
ing the local NHIF capacity. Legislation changes should be made in chapter 12 of 
the Drug act, article 45 of the Insurance act and to be created new section within 
chapter 4 of Ordinance 10 of NHIF. RSA implementation will improve the access to 
lifesaving treatment options for the patients with unmet medical needs while the 
scarce NHIF budget will be preserved within endorsed limits. conclusions: RSA 
seems promising solution for balancing uncertainties for payers with market access 
for new and existing medicines, thus will allow NHIF efficiently to control and spend 
their limited budget while providing quality treatment to more patients in need.
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BAckground: Achieving universal health coverage (UHC) is a common goal world-
wide. As off today only some rich countries have succeeded to provide publically 
funded UHC to all their citizens. However, many low- and middle-income countries 
with a weak tax base are still far from achieving similar coverage despite a con-
tinuous increase in public and private healthcare expenditure. Patients in these 
countries have to rely on direct payments to finance their health care needs and in 
some regions these out-of-pocket (OOP) payments can account for up to 80 percent 
of total health expenditure. discussion: OOP represents a significant financial 
risk to households. Low-income families, in particular, are very vulnerable and run 
the risk of further impoverishment if they have to carry both health expenditures 
and indirect costs (loss of productivity) associated with their illness. Alongside 
public and out-of-pocket spending for covering patients private health insurance 
(PHI) represents an important third source of healthcare funding. PHI allows for 
risk-sharing and as such could play a critical role in securing low-income families 
access to treatment. So far, the contribution of PHI versus UHC remains limited but 
it is expected to grow significantly in the near future in emerging markets such 
as BRICS where it will be an important player for expanding the reach of novel 
treatments. The rapid economic growth, increased demand and gaps in healthcare 
coverage will pave the way for a greater uptake of PHI. In some African countries, 
despite PHI being urgently needed, extreme poverty may favor community based 
health insurance. conclusion: Due to the low tax base in developing countries 
UHC has problem to develop thus exposing the low/medium income households 
to high financial risk. Extending PHI in those countries allows for risk sharing and 
thus could have important equity implications.
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This study examines; along with current situation in Turkey, pharmaceutical pricing 
methods, reimbursement methods and basic health indicators, within the scope 
of changing pharmaceutical policies, in Turkey, reference countries and the United 
Kingdom, the implementations of which are of utmost importance for other coun-
tries. Upon the research conducted, it was detected that the pharmaceutical pricing 
in Turkey has been performed on the basis of reference pricing system that takes 
Italy, Portugal, Spain, Greece and France as reference. The regulations regarding the 
reimbursement process are determined by SSI. The reimbursement system has been 
changed numerous times and the discount rates has incrementally risen. In pricing, 
on the other hand, drug companies face difficulties in economic terms because of 
the fact that price discount of high rates are implemented over the reference price 
and that the European currency of Euro is fixed at 2. Moreover, it has also been 
recognized that certain drugs have been hard to find within the market and the 
patients’ access to medicines has become hindered. Although it is natural for Turkey 
to put restrictions on drugs budget to ensure sustainable drug financing, in order to 
maintain the existence of pharmaceutical industry and protect the patients’ access 
to medicines; it would be more favorable in the development of the industry that the 
expectations of the stakeholders in the industry are taken into account in the policy 
making process. This would also help the already supported R&D activities to be 
sustainable as well. The positive and negative aspects of Turkey’s offering the least 
expensive medicine should be examined. Whether being the country to supply the 
least expensive medicine is the correct objective or not in the international arena 
should seriously be discussed. It is recommended that how this situation affects 
Turkey’s image in the outer world should be scrutinized.
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Since 2004 public provision of ARV in Dominican Republic (DR) has been funded, 
by the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM). Until 2009 
there was a gross correspondence between the increase in the number of treated 
cases and the funding. From 2009 to 2012, however, the number of cases grew at 
an average rate of 33.4% (2,958 cases) per year, whereas funding experienced an 
average decrease of 21.7% (965,382 USD) per year. In 2012, the Ministry of Health 
(MoH) carried out the first national quantification exercise for the 2013 procure-
ment of medicines, under a standard forecasting methodology. The cost of ARV 
was estimated in USD 6.1 million; of which the GFATM would cover USD 3.6 million 
(59%). This was the first time that a financial gap of about USD 2.5 million (41%) was 
identified and recognized by all stakeholders. A political incidence and advocacy 
strategies based on evidence were established for national authorities, NGO’s and 
